Teva Pharmaceutical announced its acceleration phase strategy targeting a $5 billion innovative medicines franchise by 2030, driven by existing products AUSTEDO, AJOVY, and UZEDY plus five late-stage pipeline assets.
Teva Pharmaceutical exceeded Q4 expectations with $4.2 billion in revenue and $0.71 earnings per share, demonstrating successful execution of their Pivot to Growth strategy.
Teva Pharmaceutical delivered Q4 2024 earnings of $0.71 per share, surpassing analyst consensus of $0.70, with revenue reaching $4.2 billion against expected $4.12 billion.
The FDA approved mirikizumab (Omvoh) for Crohn's disease, marking its second approval in IBD after ulcerative colitis, based on positive Phase 3 trial results.